Dose-related effects of smallpox vaccine

New England Journal of Medicine

Volumn 346, Issue 17, 2002, Pages 1275-1280

  Frey, Sharon E ^a   Newman, Frances K ^a   Cruz, John ^b   Brian Shelton, W ^a   Tennant, Janice M ^a   Polach, Tamara ^a   Rothman, Alan L ^b   Kennedy, Jeffrey S ^b   Wolff, Mark ^c   Belshe, Robert B ^a   Ennis, Francis A ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SMALLPOX VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; MEMBRANE VESICLE; NORMAL HUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMALLPOX; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINIA VIRUS; VERTIGO; VIRUS ISOLATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; INTERFERON TYPE II; SMALLPOX; SMALLPOX VACCINE; T-LYMPHOCYTES, CYTOTOXIC; VARIOLA VIRUS; VIRUS REPLICATION;

EID: 0037171711     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa013431     Document Type: Article

References (22)

1. Smallpox: Clinical and epidemiologic features
2. Declaration of global eradication of smallpox
3. About the first National Symposium on Medical and Public Health Response to Bioterrorism
4. Bioterrorism: How prepared are we?
5. Vaccines in civilian defense against bioterrorism
6. Progressive vaccinia with normal antibodies: A case possibly due to deficient cellular immunity
7. Progressive vaccinia in immunologically-deficient individuals
8. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
9. Smallpox vaccine no longer available for civilians - United States
10. Vaccination of vaccinianaive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial
11. The effect of the virus-serum incubation period upon vaccinia virus serum neutralization titers
12. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): Measurement of human anti-PA antibodies
13. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: Bulk culture proliferation, clonal analysis, and precursor frequency determination
14. Human cytotoxic T-cell memory: Long-lived responses to vaccinia virus
15. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans
16. A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles
17. Immunologic responses to vaccinia vaccines administered by different parenteral routes
18. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of admin istration: Primary percutaneous vaccination
19. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: Identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3 and the structural protein E
20. Complications of smallpox vaccination, 1968: National surveillance in the United States
21. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration: Primary subcutaneous vaccination